796967-16-3 Linifanib AKSci SYN1002
 
 
Loading Please Wait...
  SYN1002    
Linifanib
, >95% (HPLC)
 
ABT-869
AL-39324
RG3635




IDENTITY
CAS Number:796967-16-3
MDL Number:MFCD11840918
MF:C21H18FN5O
MW:375.41
SPECIFICATIONS & PROPERTIES
Min. Purity Spec:>95% (HPLC)
Physical Form (at 20°C):Solid
Long-Term Storage:Store long-term at -20°C
DOT/IATA TRANSPORT INFORMATION
Not hazardous material

BIOLOGICAL INFO
Solubility:DMSO 75mg/mL, Ethanol 5mg/mL
Application(s):PDGFR

REVIEW

 Linifanib (A 741439; A-741439; A741439; ABT-869; ABT869; RG3635) is an orally active multi-targeted receptor tyrosine kinase inhibitor for the treatment of various cancers. The compound is designed to inhibit vascular endothelial growth factor and platelet-derived growth factor receptors and is a multitargeted tyrosine kinase receptor inhibitor that suppresses FLT3 signaling. It is in phase III development for liver cancer and phase II development for non-small cell lung cancer, breast cancer, and colorectal cancer in the US, the EU and other areas of the world. (PMID:20698720); Recent research also indicates that Linifanib inhibits proliferation and induces apoptosis in AML patient cells via reduction of AKT and GSK3beta phosphorylation and maybe influential in AML therapy. (PMID:21471285)

GLOBALLY HARMONIZED SYSTEM (GHS)

Pictograms

Signal Word
Warning

Hazard Statements
H315; H319; H335

Precautionary Statements
P261; P264; P271; P280; P302+P352; P304+P340; P305+P351+P338; P312; P321; P332+P313; P337+P313; P362; P403+P233; P405; P501


Current as of October 6, 2022


Download SDS Request COA

⚠️
These chemical products are for research and development use only. They are not for diagnostic, therapeutic, cosmetic, or human and animal uses. They are not sold to individuals. Additional restrictions may apply.
New customers undergo an internal onboarding process. As part of this process, new customers may be asked for more information.



PubChem